Latest filing published 31 Mar 2026 for Biolife Solutions INC, €43k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Karen A. Foster (senior executive) discloses dealings in Biolife Solutions Inc to SEC (Form 4). In total, 91 filings cover trades dated from 24 May 2021 to 23 March 2026.
The open-market record consists of 60 sales worth €2.7M, with no purchase. Outside the open market, there are 22 share grants and 9 option exercises. In 2026 alone, the filings show no purchases and 4 sales.
The latest filing, published on 31 March 2026, reports an open-market sale of €43k in Biolife Solutions Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 91 declarations